research use only

(E/Z)-Polydatin Phospholipase (e.g. PLA) inhibitor

Cat.No.S2390

(E/Z)-Polydatin is a mixture of cis- and trans-configurations of Polydatin.
(E/Z)-Polydatin Phospholipase (e.g. PLA) inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 390.38

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 390.38 Formula

C20H22O8

Storage (From the date of receipt)
CAS No. 65914-17-2 Download SDF Storage of Stock Solutions

Solubility

In vitro
Batch:

DMSO : 78 mg/mL ( (199.8 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
PLA2 [1]
In vitro
Polydatin, known as a PLA2 inhibitor, reduces Phospholipase A2 (PLA2) activity and sPLA2-IIA mRNA expression and mitigates LPS-induced lung injury by increasing increased Clara cell secretory protein (CCSP) expression. [1]
In vivo
Pretreatment with Polydatin (15, 45, and 100 mg/kg) dose-dependently reduces sepsis-induced mortality and lung injury in cecal ligation and puncture (CLP-)induced sepsis mice through inhibiting CLP-induced serum tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) production, lung cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase isoform (iNOS) protein expressions and NF-kappaB activation. [2] LD50: Mice 1g/kg (i.p.) [3]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01370720 Unknown status
Irritable Bowel Syndrome
MARIA CRISTINA COMELLI|CM&D Pharma Limited
February 2010 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map